Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.

Current President and CEO, Samir R. Patel, M.D., to remain as a member of the Company’s Board of Directors BOSTON and LONDON, ...

NORTH CHICAGO, IL, USA I March 15, 2025 I AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the ...

MacroGenics (NASDAQ: MGNX) Q4 2024 Earnings Call Mar 20, 2025, 4:30 p.m. ET ...

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio ...

Other big financings this week Swiss biotech Alentis Therapeutics raised more than $181 million in a Series D that will support clinical trials of two antibody-drug conjugates (ADCs) targeting ...

Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating ...

PHYSICOCHEMICAL characterization of components of flagella and cilia is essential for an understanding of the mechanisms underlying flagellar and ciliary movement. The so-called “9 + 2” fibres ...

During the past 20 years, the advent of neoadjuvant, primary, and adjuvant concurrent chemoradiotherapy has improved cancer care dramatically. Significant contributions have been made by ...